The Utility of Urinary NGAL as an Alternative for Serum Creatinine to Detect Acute Kidney Injury in Infants Exposed to Nephrotoxic Medications in the Neonatal Intensive Care Unit
Neonatology · 2024
DOI: 10.1159/000535322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neonatology, 2024. Verfasst von Christine Stoops und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Intensive Care Units, Neonatal, Acute Kidney Injury. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS.
Themen: Neonatologie, Intensivpflege
Abstract (Originalsprache)
Introduction
Nephrotoxic medication (NTM) exposure is commonly associated with acute kidney injury (AKI) in the neonatal intensive care unit (NICU). Baby Nephrotoxic Injury Negated by Just-in-Time Action (NINJA) is a quality improvement program that assesses for AKI in those exposed to NTM with daily serum creatinine (SCr) levels. However, blood draws for SCr are invasive and have clinical disadvantages. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) is a promising indicator of AKI. We tested the hypothesis that uNGAL could reliably screen for NTM-AKI in the Baby NINJA program.
Methods
This two-center prospective study screened 174 NICU subjects, of whom 148 met screening criteria from January 29, 2019, to September 18, 2020. Daily SCr and urine samples were obtained for up to 7 days of NTM exposure plus 2 days after exposure ended or end of AKI. AKI was defined by a SCr rise of 50% from baseline. The highest uNGAL obtained was evaluated to determine its relationship to the diagnosis of AKI. Logistic regression models were used to determine optimal uNGAL cutoffs.
Results
The negative predictive value of a uNGAL value ≥250 ng/mL was 96.8% (95% CI = 93.3–100%). Urine NGAL ≥400 ng/mL demonstrated the highest ROC-AUC value of 0.72 with a positive likelihood risk for AKI of 2.76 (1.39–4.13). Discussion/Conclusion: We propose that uNGAL could be used to screen for NTM-AKI and thus replace many blood draws needed in those exposed to NTM. The ideal uNGAL threshold requires further investigation in infants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Pediatrics, Children's of Alabama, Birmingham, Alabama, USA.
- Department of Pediatrics, Levine Children's Hospital, Charlotte, North Carolina, USA.
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
Zitieren
APA
Stoops, C., Gavigan, H., Krallman, K., Anderson, N., Griffin, R., Slagle, C., House, S., Goldstein, S. L., & Askenazi, D. J. (2024). The Utility of Urinary NGAL as an Alternative for Serum Creatinine to Detect Acute Kidney Injury in Infants Exposed to Nephrotoxic Medications in the Neonatal Intensive Care Unit. Neonatology. https://doi.org/10.1159/000535322
Vancouver
Stoops C, Gavigan H, Krallman K, Anderson N, Griffin R, Slagle C, et al. The Utility of Urinary NGAL as an Alternative for Serum Creatinine to Detect Acute Kidney Injury in Infants Exposed to Nephrotoxic Medications in the Neonatal Intensive Care Unit. Neonatology. 2024. doi:10.1159/000535322
BibTeX
@article{Stoops2024,
author = {Stoops, Christine and Gavigan, Hailey and Krallman, Kelli and Anderson, Nekayla and Griffin, Russell and Slagle, Cara and House, Scott and Goldstein, S L and Askenazi, D J},
title = {The Utility of Urinary NGAL as an Alternative for Serum Creatinine to Detect Acute Kidney Injury in Infants Exposed to Nephrotoxic Medications in the Neonatal Intensive Care Unit},
journal = {Neonatology},
year = {2024},
doi = {10.1159/000535322}
}
EUVIMED